ARTICLE SUMMARY:
Organon wants to become the partner of choice for medical device, diagnostic, pharmaceutical, and digital health companies offering solutions for women’s health, and this is good news for innovative companies working in the space.
A CEO at a women’s medical device start-up recently told MedTech Strategist that when he was originally sussing out the opportunity, one of his peers told him, “You don’t want to go there. Women’s health is risky and there haven’t been blockbuster exits.” It’s exactly this type of message that has stymied investment—and therefore innovation—in women’s health, but that story might be changing.
For more than a year, Merck & Co. has been working out the details of creating a premier women’s health company that embraces not only Merck’s pharmaceutical heritage, but solutions that could come from the medical device, diagnostics, or digital health industries. The spin-out is final: Organon & Co. will become an independent, NYSE-traded public company on June 3.
